Cargando…
Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies
The rates of type 2 diabetes mellitus, obesity, and cardiovascular disease (CVD) continue to increase at epidemic proportions. It has become clear that these disease states are not independent but are frequently interrelated. By addressing conditions such as obesity, insulin resistance, stress hyper...
Autores principales: | Schwartz, Stanley, Kohl, Benjamin A |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3047965/ https://www.ncbi.nlm.nih.gov/pubmed/21437091 |
Ejemplares similares
-
Comparison of efficacy between incretin-based therapies for type 2 diabetes mellitus
por: Nisal, Kaustubh, et al.
Publicado: (2012) -
Potentials of incretin‐based therapies in dementia and stroke in type 2 diabetes mellitus
por: Groeneveld, Onno N, et al.
Publicado: (2015) -
Renoprotective Effects of Incretin-Based Therapy in Diabetes Mellitus
por: Yaribeygi, Habib, et al.
Publicado: (2021) -
Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitus
por: Cobble, Michael
Publicado: (2012) -
Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus
por: Koliaki, Chrysi, et al.
Publicado: (2011)